Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer

Inclusion Criteria: * Disease characteristic: * Histologically confirmed primary breast cancer by core biopsy (Mammotome or bard needle) * Disease stage appropriate for neoadjuvant chemotherapy (T≥3cm, N0 or T（2-3cm）N1 or any T, N2) * Her-2(-); Ki67≥14% * No previous treatment for breast cancer (chemotherapy, endocrinotherapy, radiotherapy) * Patients characteristic: * Female patients, age 18 to 70 years old * Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-2 * Life expectancy of at least 12 weeks * Willing to be kept follow-up * Functions below are maintained in major organs: * Cardiac status: LVEF: 50% 45% • Haematopoietic status: Leukocyte count: ≥4.0×109/L Neutrophil count: ≥2.0×109/L Platelet count: ≥100×109/L Hemoglobin: ≥80g/L • Hepatic status: Total Bilirubin ≤ 1.5 x upper limit of normal (ULN), AST and ALT ≤ 2.5 times ULN(no liver metastasis) bilirubin: • Renal status: BUN ≤ 1.5 x times ULN Creatinine ≤1.5 times ULN or calculated creatinine clearance, using the Cockcroft-Gault formula, ≥50 mL/min; Women's Ccr = Body weight x (140-Age)/(72 x Serum creatinine) x 0.85 • Written informed consent (both biopsy and neoadjuvant chemotherapy) will be obtained for patients for entering this study Exclusion Criteria: * Previous treatment for breast cancer (neither local nor systemic therapy) * Known or suspected distant metastasis * Potentially pregnant, pregnant, or breast-feeding * Drug allergy * Concurrent malignancy or history of other malignancy (except Hodgkin lymphoma) * Currently active severe infection (Hepatitis included) * History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures * Known history of uncontrolled severe heart disease, myocardial infarction within 6 months, congestive heart failure, unstable angina pectoris, clinically significant hydropericardium or unstable arrhythmias